ReviewCritical care (London, England)2018
Vasoplegia treatments: the past, the present, and the future.
Review in Critical care (London, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 103 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Angiotensin II Stress Test. Renin Kinetics During Treatment of Vasoplegic Shock With Angiotensin II in Relation to Hemodynamic Response to Treatment With Angiotensin II.
Inotropic Effects of Vasopressin Versus Noradrenaline In Patients With Vasoplegic Syndrome After Cardiac Surgery
Who cites it
103 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- ADJUNCTIVE VASOPRESSORS AND SHORT-TERM MORTALITY IN ADULTS WITH SEPTIC SHOCK: A SYSTEMATIC REVIEW AND META-ANALYSIS.Shock (Augusta, Ga.) · 2025Pooled it
- Vasopressin in vasoplegic shock in surgical patients: systematic review and meta-analysis.Acta cirurgica brasileira · 2023Pooled it
- Ascorbic acid and microcirculation in cardiothoracic surgery: a pilot feasibility trial and matched cohort study.Journal of cardiothoracic surgery · 2025Trial
- Effect of prehospital high-dose glucocorticoid on hemodynamics in patients resuscitated from out-of-hospital cardiac arrest: a sub-study of the STEROHCA trial.Critical care (London, England) · 2024Trial
- Vaso-active inotropic scores: Clinical value, pros and cons.JHLT open · 2026Article
- Lung-Cardiovascular Interactions and Derangements in ARDS.Comprehensive physiology · 2026Review
- A nomogram for predicting 3-month mortality in colorectal cancer patients requiring perioperative ICU admission: a retrospective cohort study.World journal of surgical oncology · 2026Article
- Extracorporeal Cytokine Hemadsorption with oXirisJournal of clinical medicine · 2026Article
- Comparison of norepinephrine with a combined non-catecholaminergic therapy in a porcine model of refractory cardiac arrest resuscitated with VA-ECMO.Intensive care medicine experimental · 2026Article
- Perioperative Vasopressor Management in Noncardiac Surgical Patients.Anesthesiology · 2026Article
- Sodium ascorbate versus ascorbic acid in sepsis: a narrative review of emerging cardiovascular and neurological benefits.Critical care (London, England) · 2026Review
- Management of arterial hypotension in critically Ill children: a narrative review and practical approach.Frontiers in pediatrics · 2026Review
- Blood pressure response index and acute kidney injury progression in heart failure patients: a retrospective cohort study from MIMIC-IV.BMC nephrology · 2025Article
- Management of post-resuscitation vasoplegic shock: targets, strategies and outcomes.Critical care (London, England) · 2025Review
- Hemodynamic effects of levosimendan in low cardiac output syndrome post-CABG refractory to standard inotropic therapy.Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2025Article
- Evaluation of indexing pulse pressure variation during low tidal ventilation : An experimental pilot study.Die Anaesthesiologie · 2025Article
- ATPflugers Archiv : European journal of physiology · 2025Article
- Hydroxocobalamin for vasoplegia in cardiac surgery: a retrospective cohort analysis.British journal of anaesthesia · 2025Article
- Management of hypotension in dihydropyridine calcium channel blocker overdose: The role of high-dose insulin therapy.British journal of clinical pharmacology · 2025Article
- Insights Into the Pathophysiology of Catecholamine-Refractory Shock: A Narrative Review.Cureus · 2025Review
43 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasoplegia is a ubiquitous phenomenon in all advanced shock states, including septic, cardiogenic, hemorrhagic, and anaphylactic shock. Its pathophysiology is complex, involving various mechanisms in vascular smooth muscle cells such as G protein-coupled receptor desensitization (adrenoceptors, vasopressin 1 receptors, angiotensin type 1 receptors), alteration of second messenger pathways, critical illness-related corticosteroid insufficiency, and increased production of nitric oxide. This review, based on a critical appraisal of the literature, discusses the main current treatments and future approaches. Our improved understanding of these mechanisms is progressively changing our therapeutic approach to vasoplegia from a standardized to a personalized multimodal treatment with the prescription of several vasopressors. While norepinephrine is confirmed as first line therapy for the treatment of vasoplegia, the latest Surviving Sepsis Campaign guidelines also consider that the best therapeutic management of vascular hyporesponsiveness to vasopressors could be a combination of multiple vasopressors, including norepinephrine and early prescription of vasopressin. This new approach is seemingly justified by the need to limit adrenoceptor desensitization as well as sympathetic overactivation given its subsequent deleterious impacts on hemodynamics and inflammation. Finally, based on new pathophysiological data, two potential drugs, selepressin and angiotensin II, are currently being evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.